54 patents
Utility
Gastro Retentive Dosage Forms Comprising Deutetrabenazine
7 Dec 23
Provided herein are controlled release gastro retentive dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders.
Mayank JOSHI, Parag SHAH, Soumen PATTANAYEK, Divyang PATEL, Sandeep PANDITA
Filed: 12 Oct 21
Utility
Multiparticulate Dosage Forms Comprising Deutetrabenazine
16 Nov 23
Provided herein are controlled release multiparticulate dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders.
Mayank JOSHI, Parag SHAH, Soumen PATTANAYEK, Divyang PATEL, Sandeep PANDITA
Filed: 17 Sep 21
Utility
Analogs of deutetrabenazine, their preparation and use
14 Nov 23
The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Chengzhi Zhang, James Kerr
Filed: 15 Mar 18
Utility
Pharmaceutical Formulations
9 Nov 23
The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
Filed: 21 Feb 23
Utility
Methods for the treatment of abnormal involuntary movement disorders
16 May 23
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Fangching Huang
Filed: 2 Aug 17
Utility
Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
20 Apr 23
David Stamler
Filed: 14 Apr 22
Utility
Methods of Manufacturing Benzoquinoline Compounds
2 Mar 23
Chengzhi Zhang
Filed: 2 Aug 22
Utility
Methods for the treatment of abnormal involuntary movement disorders
31 Jan 23
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Fangching Huang
Filed: 2 Oct 17
Utility
Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof
26 Jan 23
Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders.
Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
Filed: 1 Mar 22
Utility
Methods for the Treatment of Dyskinesia In Cerebral Palsy
29 Dec 22
The disclosure is directed to methods of treating dyskinesia in cerebral palsy in human patients using deutetrabenazine and its active metabolites.
Juha-Matti Savola, Mark Forrest Gordon, Frank Schneider
Filed: 12 Apr 22
Utility
Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof
22 Sep 22
Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders.
Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
Filed: 8 Jun 22
Utility
Methods for the treatment of abnormal involuntary movement disorders
20 Sep 22
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Fangching Huang
Filed: 25 Mar 21
Utility
Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
25 Aug 22
Thomas G. Gant, Manouchehr Shahbaz
Filed: 5 Nov 21
Utility
Methods for the treatment of abnormal involuntary movement disorders
14 Jun 22
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
David Stamler, Michael Huang
Filed: 21 Jan 21
Utility
Methods for the treatment of dyskinesia in cerebral palsy
10 May 22
The disclosure is directed to methods of treating dyskinesia in cerebral palsy in human patients using deutetrabenazine and its active metabolites.
Juha-Matti Savola, Mark Forrest Gordon, Frank Schneider
Filed: 13 Dec 19
Utility
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
26 Apr 22
Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders.
Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
Filed: 10 Jun 21
Utility
Analogs of Deutetrabenazine, Their Preparation and Use
24 Mar 22
The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Chengzhi Zhang, James Kerr
Filed: 30 Nov 21
Utility
Dihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods
10 Mar 22
David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
Filed: 11 Aug 21
Utility
Analogs of Deutetrabenazine, Their Preparation and Use
10 Feb 22
The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Chengzhi Zhang, James Kerr
Filed: 21 Oct 21
Utility
Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof
16 Dec 21
Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders.
Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
Filed: 10 Jun 21